CSL Limited (ASX:CSL): What Do FY2026 Impairments and Plasma Results Signal?

Aditi Sarkar

02 November 2026 06:13 PM AEDT

CSL Limited (ASX:CSL): What Do FY2026 Impairments and Plasma Results Signal?

Image Source: Shutterstock

You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more

Start Your Free Trial Now!

Highlights

CSL reported FY2026 group Revenue of USD 15.8 billion.
Underlying NPATA attributable to shareholders was approximately USD 3.1 billion.
One-off impairments and restructuring costs materially affected statutory profit.

CSL Limited (ASX:CSL) develops and supplies plasma-derived medicines, influenza vaccines and other specialty biopharmaceutical products through CSL Behring, CSL Seqirus and CSL Vifor. Shares closed at AUD 201.22 on 2 November 2026. Its FY2026 results combined ongoing Demand across selected therapies with a statutory loss following substantial impairments and restructuring costs. The company is pursuing operational simplification while investing in Manufacturing capacity, commercial programs and product development.

FY2026 group results

For the financial year ended 30 June 2026, CSL (ASX:CSL) reported total revenue of USD 15.797 billion. Underlying net profit after tax and Amortisation attributable to ordinary shareholders was USD 3.098 billion, down 2% on a constant-currency basis. The company reported a statutory net loss of approximately USD 2.6 billion, reflecting substantial restructuring, Impairment and related costs. Its investor presentation identified approximately USD 7.1 billion of impairment and related costs and approximately USD 0.8 billion of pre-tax restructuring costs. Underlying and reported profit measures therefore describe materially different outcomes and must not be used interchangeably.

Segment revenue and operations

CSL Behring recorded FY2026 revenue of USD 11.387 billion, while CSL Seqirus generated USD 2.031 billion and CSL Vifor reported USD 2.379 billion. CSL (ASX:CSL) described continued demand for immunoglobulin therapies and momentum in selected newer medicines. Seqirus operated in a challenging influenza market, while Vifor faced competition affecting its iron portfolio. The company opened a cell-based Vaccine manufacturing Facility in Melbourne and discussed Investment in additional plasma-derived therapy manufacturing capacity in the United States. These activities create operating and Capital requirements extending beyond the reported fiscal year.

Operating cash and transformation

CSL (ASX:CSL) reported Operating Cash Flow of USD 3.512 billion for FY2026. Management disclosed cost savings of USD 176 million from transformation initiatives and completion of an approximately AUD 1 billion share buyback. The company has sought to simplify its operating structure while investing in commercial and development programs. Cash generation supports these activities, but restructuring charges, manufacturing expenditure and future program commitments require separate assessment. The reported cash balance alone would not establish the ultimate cost of planned manufacturing or product-development activity.

Risks and FY2027 expectations

CSL (ASX:CSL) faces product competition, plasma collection costs, manufacturing complexities, healthcare regulation and clinical-development risks. Its FY2027 outlook included expected mid-single-digit constant-currency Behring revenue growth and low-single-digit Seqirus revenue growth, while warning of pressure on Vifor from generic iron competition and the Withdrawal of TAVNEOS in European markets. Those statements are management expectations, not achieved results. The scale of impairments also highlights the need to evaluate asset valuations and returns on investment. Changes in clinical evidence, product approvals and manufacturing efficiency could affect later reporting periods. CSL has also disclosed the opening of its Tullamarine vaccine facility, which adds manufacturing capability but entails continued operational and maintenance requirements. New product uptake should be monitored against costs of commercialisation and research, rather than assuming that a regulatory milestone will translate immediately into earnings. The interim Leadership and announced organisational changes add execution considerations during FY2027.

Key Insights

CSL Limited (ASX:CSL) provides an example of how completed FY2026 results and 2026 operating developments must be read together. Revenue, profit, cash generation and any development or restructuring expenditure describe different dimensions of financial performance. The disclosed figures should be assessed alongside execution milestones, the scope of regulatory approvals and identified business risks. The closing price on 2 November 2026 is a dated market observation, not a measure of future operating results.

Download Free Report – Explore 3 Stock Ideas & Industry Insights

Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.

All investments involve risk—consider independent advice before making any investment decisions.

View 3 Research Reports

Disclaimer:

This article (“Article”) has been prepared by Kalkine Pty Limited (ABN 34 154 808 312) (Australian financial services licence number 425376) (“Kalkine”) and its related bodies corporate who are authorised to provide general financial product advice. Kalkine.com.au and its associated pages are published by Kalkine.

Any information/advice provided in this article is general in nature and does not take into account your objectives, financial situation or needs. You should therefore consider whether the information is appropriate for your objectives, financial situation and needs before acting upon it.

There may be a Product Disclosure Statement, Information Memorandum or other offer document (“Offer Document”) for the securities or other financial products referred to in Kalkine articles. You should obtain a copy of the Offer Document and consider it before making any decision about whether to acquire the security or financial product.

Kalkine strongly recommends that you seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) before acting on any advice/information in this Article or on the Kalkine website. Not all investments are appropriate for all people.

The information in this Article and on Kalkine website has been prepared from a wide variety of sources, which Kalkine, to the best of its knowledge and belief, considers accurate. Kalkine has made every effort to ensure the reliability of the information contained in its articles (including this Article), newsletters and websites. All information represents our views at the date of publication and may change without notice.

The information in this Article does not constitute an offer to sell securities or other financial products or a solicitation of an offer to buy securities or other financial products.

Kalkine does not issue, sell or deal in any financial products.

This Article may contain information on past performance of particular investments. Please note past performance is neither an indicator nor a guarantee of future performance.

To the extent permitted by law, and excluding any dishonesty or gross negligence by Kalkine, Kalkine disclaims and excludes all liability for any direct, indirect, implied, punitive, special, incidental or other consequential loss or damage arising from the use of or reliance on this Article, the Kalkine website and any information published on the Kalkine website without any warranties or representations by Kalkine to you. To the extent the law prohibits or limits this exclusion, Kalkine limits its liability to the resupply of services.

Please also read our Terms & Conditions and Financial Services Guide for further information.

Employees and/or associates of Kalkine and its related entities may hold interests in the securities or other financial products covered in this Article or on the Kalkine website. Any such employees and associates are required to comply with certain safeguards, procedures and disclosures as required by law.

Some of the images/music that may be used in the Article are copyright to their respective owner(s). Kalkine does not claim ownership of any of the pictures displayed/music used in the Article unless stated otherwise. The images/music that may be used in the Article are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated or was found to be necessary.

Kalkine Media Pty Ltd, an affiliate of Kalkine Pty Ltd, may have received, or be entitled to receive, financial consideration in connection with providing information about certain entity(s) covered on its website.